tirzepatide surpass-4 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Effects of tirzepatide versus insulin

SURMOUNT-1 results by dose The landmark SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight (BMI of 30 or higher, or 27 or higher with at least one weight-related complication)

If you consistently overdose by 20% due to syringe reading errors (drawing 30 units instead of 25 from a 10 mg/mL vial), you are actually taking 3 mg per week instead of 2.5 mg

After 2 to 3 weeks at each dose, you will have enough information to optimize your timing specifically for that dose level

Tirzepatide takes approximately three to four weeks to reach steady-state blood levels at any given dose

They can assess the specific circumstances and provide personalized advice on whether the medication is still safe to use

Czernichow S, et al